Brief: Celyad Oncology End-Sept Cash At 6.1 Million Euros

Celyad Oncology SA

11/11/2021 06:53

Nov 11 (Reuters) - CELYAD ONCOLOGY  CYAD.BR :
    * ANNOUNCED ON WEDNESDAY THIRD QUARTER 2021 FINANCIAL
RESULTS AND
RECENT BUSINESS HIGHLIGHTS
    * AS OF SEPT 30, HAD CASH AND CASH EQUIVALENTS OF €6.1
MILLION
($7.1 MILLION), REPRESENTING A DECREASE IN CASH AND CASH
EQUIVALENTS OF €5.9 MILLION AS COMPARED TO JUNE 30
    * BELIEVES ITS EXISTING CASH AND CASH EQUIVALENTS SHOULD BE
SUFFICIENT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE
REQUIREMENTS TO THE END OF Q3 2022
    * PHASE 1B KEYNOTE-B79 TRIAL SET TO EVALUATE CYAD-101
FOLLOWED BY
KEYTRUDA® IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS WITH
MICROSATELLITE STABLE DISEASE ON TRACK TO BEGIN BY YEAR-END 2021
    * ADDITIONAL DATA FROM THE PHASE 1 IMMUNICY-1 TRIAL OF
CYAD-211
AND THE PHASE 1 CYCLE-1 TRIAL OF CYAD-02 ARE EXPECTED AT THE
UPCOMING ASH MEETING IN DECEMBER 2021
    * SUBMISSION OF THE IND APPLICATION FOR CYAD-203 FOR
TREATMENT OF
SOLID TUMORS IS EXPECTED IN MID-2022

      
 Source text for Eikon:  urn:newsml:reuters.com:*:nBw3PFgxqa
 Further company coverage:  CYAD.BR  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))